NCT02469987 - Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Healthy

Interventions

DRUG

MYL-1402O

Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.

DRUG

US marketed Avastin(R)

Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins

DRUG

EU marketed Avastin(R)

Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.

Trial Locations (1)

PRA Health Sciences - Early Development Services, Zuidlaren